Yousef Kayed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yousef Kayed has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Sahar AbdElRaouf
Associate Professor and Acting Head of Biochemistry Department at Misr international university (MIU), Egypt
2 shared publications - Wafaa N. Eltayeb
Department of Microbiology, Faculty of Pharmacy, Misr International University (MIU), Cairo 19648, Egypt
2 shared publications
Latest Publications
- Open Access
- 25 July 2025
- Published by AccScience Publishing in Microbes & Immunity
GB virus C as a potential vaccine against human immunodeficiency virus: A review
Human immunodeficiency virus (HIV) is a pathogenic virus capable of entering the human body and replicating within T cells, ultimately leading to acquired immunodeficiency syndrome. In contrast, GB-virus C (GBV-C), a member of the Flaviviridae family, also infects humans but, according to current studies, is not associated with any known pathogenic effects. Unlike most RNA viruses, GBV-C encodes a single polyprotein. It is primarily transmitted through blood and sexual contact. GBV-C comprises three strains: GBV-C, hepatitis G virus (HGV), and other less-studied strains. The HGV strain has been detected in patients with liver cirrhosis; however, there is no evidence that it causes liver disease. Notably, GBV-C reduces immune activation in HIV-infected patients. It has been shown to have a significant effect on the target cell receptors for HIV, indicating its potential as a model for vaccine development against HIV. However, there is a lack of information and studies concerning this virus. GBV-C-based vaccine development faces many challenges, such as concerns about safety and efficacy, limited understanding of its mechanisms of action and immunogenicity, HIV strain variability, ethical and regulatory considerations, production and delivery logistics, long-term outcomes, and public perception and acceptance. Nevertheless, bioinformatic techniques can play a crucial role in overcoming these challenges through approaches such as comparative genomics, epitope mapping, structural bioinformatics, and vaccine design and optimization.
- 25 July 2025
- Published by AccScience Publishing in Microbes & Immunity
Open AccessGB virus C as a potential vaccine against human immunodeficiency virus: A review
Human immunodeficiency virus (HIV) is a pathogenic virus capable of entering the human body and replicating within T cells, ultimately leading to acquired immunodeficiency syndrome. In contrast, GB-virus C (GBV-C), a member of the Flaviviridae family, also infects humans but, according to current studies, is not associated with any known pathogenic effects. Unlike most RNA viruses, GBV-C encodes a single polyprotein. It is primarily transmitted through blood and sexual contact. GBV-C comprises three strains: GBV-C, hepatitis G virus (HGV), and other less-studied strains. The HGV strain has been detected in patients with liver cirrhosis; however, there is no evidence that it causes liver disease. Notably, GBV-C reduces immune activation in HIV-infected patients. It has been shown to have a significant effect on the target cell receptors for HIV, indicating its potential as a model for vaccine development against HIV. However, there is a lack of information and studies concerning this virus. GBV-C-based vaccine development faces many challenges, such as concerns about safety and efficacy, limited understanding of its mechanisms of action and immunogenicity, HIV strain variability, ethical and regulatory considerations, production and delivery logistics, long-term outcomes, and public perception and acceptance. Nevertheless, bioinformatic techniques can play a crucial role in overcoming these challenges through approaches such as comparative genomics, epitope mapping, structural bioinformatics, and vaccine design and optimization.
- Open Access
- 6 February 2025
- Published by MDPI AG in Preprints.org
GB Virus C; Discussing the Possibility of Using GB Virus-C (GBV-C) as a Vaccine Against HIV and Reawakening the Scientific Community About GBV-C
Human immunodeficiency virus (HIV ) is one of the pathogenic viruses that enter the human body and replicate in T-cells, leading to acquired immunodeficiency syndrome ( AIDS). On the other hand, GB-virus C (GBV-C) is a virus that enters the human body without known pathogenic effects on the human body. It is mostly related to the Flaviviridae family, especially hepatitis C (HCV).To our knowledge, studies show that this virus is not associated with any disease. The viral composition differs from most known RNA viruses as it encodes a single polyprotein. The virus could be transmitted through blood and sexual contact. The GBV-C includes three different strains: GBV-C, Hepatitis G virus (HGV), and non-studied one. HGV strain has been detected in patients with liver cirrhosis. However, there is no evidence that it causes liver disease. GBV-C reduces immunity activation in HIV-infected patients. It has been found that it has a marked effect on the target cell receptors for HIV indicating that it could be studied to design a vaccine against HIV. However, there is a lack of information and studies concerning the virus. Many challenges are faced when developing a vaccine based on a virus. These challenges include safety and efficacy, mechanism of action for GBV-C, immunogenicity, variability in HIV Strains, ethical and regulatory issues, production and delivery, long-term outcomes, and public perception and acceptance. However, bioinformatics techniques can play a crucial role in overcoming these challenges by several methods that are: comparative genomics, epitope mapping, structural bioinformatics, and vaccine design and optimization.
- 6 February 2025
- Published by MDPI AG in Preprints.org
Open AccessGB Virus C; Discussing the Possibility of Using GB Virus-C (GBV-C) as a Vaccine Against HIV and Reawakening the Scientific Community About GBV-C
Human immunodeficiency virus (HIV ) is one of the pathogenic viruses that enter the human body and replicate in T-cells, leading to acquired immunodeficiency syndrome ( AIDS). On the other hand, GB-virus C (GBV-C) is a virus that enters the human body without known pathogenic effects on the human body. It is mostly related to the Flaviviridae family, especially hepatitis C (HCV).To our knowledge, studies show that this virus is not associated with any disease. The viral composition differs from most known RNA viruses as it encodes a single polyprotein. The virus could be transmitted through blood and sexual contact. The GBV-C includes three different strains: GBV-C, Hepatitis G virus (HGV), and non-studied one. HGV strain has been detected in patients with liver cirrhosis. However, there is no evidence that it causes liver disease. GBV-C reduces immunity activation in HIV-infected patients. It has been found that it has a marked effect on the target cell receptors for HIV indicating that it could be studied to design a vaccine against HIV. However, there is a lack of information and studies concerning the virus. Many challenges are faced when developing a vaccine based on a virus. These challenges include safety and efficacy, mechanism of action for GBV-C, immunogenicity, variability in HIV Strains, ethical and regulatory issues, production and delivery, long-term outcomes, and public perception and acceptance. However, bioinformatics techniques can play a crucial role in overcoming these challenges by several methods that are: comparative genomics, epitope mapping, structural bioinformatics, and vaccine design and optimization.